Latest Strategic Pivot News

Province Resources Limited reported a stable cash position of $9.27 million in its December 2024 quarter, while continuing discussions on its HyEnergy® project and evaluating new gold and commodity opportunities.

Equus Mining Limited reported a $750,000 final settlement from Andean Silver and is actively exploring new investment opportunities, maintaining a cash reserve of $535,000 as of December 2024.

MONEYME reports a 54% surge in loan originations and a $1.4 billion loan book in 2Q25, underpinned by fresh growth capital and a strategic shift to secured lending.

Lendlease has agreed to sell Capella Capital for $235 million and completed the $516 million sale of its US Military Housing business, reinforcing its strategy to streamline operations and reduce funding needs.

Askari Metals reports significant exploration advances across its Australian gold and copper projects and secures a new uranium project in Tanzania, supported by fresh funding and leadership updates.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.

Fluence Corporation Limited delivered a standout Q4 2024 with $21.2 million revenue and $1 million EBITDA, driven by a strategic shift to higher-margin Smart Product Solutions. The company’s robust $88 million backlog and $50 million in new orders set the stage for ambitious growth in 2025.

Centrex Limited stabilises operations at Ardmore Mine, completes Australia’s first phosphate export to India, and launches a $10.4 million entitlement offer to fund expansion.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Gas2Grid navigates regulatory headwinds in Australia by pursuing new petroleum ventures in the Philippines while contesting a significant legal claim in France. The company’s ASX suspension persists as it seeks to restore compliance through fresh contracts.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.